Pharma sees red as India allows Natco to produce patented Nexavar at 3% of Bayer's price
This article was originally published in Scrip
Executive Summary
India has approved its first ever compulsory licence in the area of medicines for Bayer's anticancer Nexavar (sorafenib tosylate), allowing the domestic firm Natco Pharma, to self manufacture and sell a version of Nexavar for just over 3% of the price that Bayer sells the drug for in India.
You may also be interested in...
Natco CEO On Dynamics In The HCV Market
Nexavar compulsory license holder Natco Pharma is counted among the leading players in the Indian oncology market and now looks to be aiming for an encore in the hepatitis C segment. Natco vice chair and CEO Rajeev Nannapaneni talks to Scrip of the large patient numbers on HCV therapy and outlines a potential market "split" in certain rest of the world (RoW) territories with the arrival of Gilead's Epclusa.
India Compulsory Licensing: What USTR Hearing Transcripts Say
Private assurances or not, the prickly debate around the use of compulsory licenses in India appears to have an ongoing subtext going by the transcript of statements by the US-India Business Council (USIBC) before the United States Trade Representative (USTR) at the 2016 Special 301 review public hearing.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.